View ValuationHeartseed 향후 성장Future 기준 점검 2/6Heartseed (는) 각각 연간 0.7% 및 41% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 1.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -37% 로 예상됩니다.핵심 정보0.7%이익 성장률1.51%EPS 성장률Biotechs 이익 성장38.5%매출 성장률41.0%향후 자기자본이익률-37.03%애널리스트 커버리지Low마지막 업데이트18 May 2026최근 향후 성장 업데이트공시 • Feb 14Heartseed Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026Heartseed Inc. provided non-consolidated earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects net sales of JPY 451 million, Operating loss of JPY 2,207 million, Loss of JPY 2,158 million and Basic loss per share of JPY 95.58.공시 • Oct 18Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. revised earnings guidance for the fiscal year ending October 31, 2024. For the year, the company expects net sales of JPY 874 million compared to Previous forecast of JPY 153 million, Operating loss of JPY 1,059 million compared to Previous forecast of JPY 1,965 million, net income of JPY 891 million compared to Previous forecast of JPY 1,798 million, and Net loss Per Shares of JPY 54.32 compared to Previous forecast of JPY 109.09.공시 • Sep 13Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. provided earnings guidance for the fiscal year ending October 31, 2024. For the fiscal year, the company expected net sales of JPY 153 million, Operating loss of JPY 1,965 million, Net loss of JPY 1,798 million and Net loss per share of JPY 109.09.모든 업데이트 보기Recent updatesNew Risk • Jun 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2025 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change).공시 • Jun 12Heartseed Announces First Patient Dosed In Phase I/II Clinical Trial Of HS-005 For Cardiac Remuscularization TherapyHeartseed Inc. announced that the first patient with heart failure caused by dilated cardiomyopathy has been dosed in the domestic clinical trial (EMERALD study) of HS-005 (allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter), which is being developed by the Company. The Independent Safety Monitoring Committee approved the continuation of the trial for dilated cardiomyopathy cohort based on the evaluation of four-week post-administration data from this case. This trial is a company-sponsored clinical trial aimed at expanding the application of the therapy not only to severe heart failure caused by ischemic heart disease, but also by dilated cardiomyopathy. A total of 14 patients, consisting of seven patients in each disease cohort, will be enrolled to evaluate the safety and efficacy of the therapy. There is no revision to the latest earnings forecast for the fiscal year ending December 31, 2026. Heartseed Inc. announced the successful dosing of the first patient in its domestic Phase I/II clinical trial (EMERALD study) of HS-005, allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter, targeting severe heart failure caused by ischemic heart disease or dilated cardiomyopathy. This study marks the world's first clinical trial to administer iPS cell-derived cardiomyocyte spheroids using a catheter. HS-005 is a therapeutic program currently under development, in which allogeneic iPS cell-derived cardiomyocyte spheroids (micro-tissues of cardiomyocytes) produced based on Heartseed's proprietary technology are administered into the patient's myocardium using a dedicated delivery catheter system. While Heartseed's lead pipeline, HS-001, requires open-heart surgery, HS-005 utilizes a catheter for delivery from the inside of the heart (endocardial delivery), aiming to realize a next-generation, minimally invasive cardiac regenerative medicine. Heartseed has been advancing the EMERALD study in Japan aiming at the development of HS-005, and the administration to the first patient suffering from heart failure due to dilated cardiomyopathy was successfully completed in late March 2026 at Shinshu University Hospital. The patient's postoperative course has been generally uneventful, and the patient has already been discharged from the hospital. The independent Safety Monitoring Committee has evaluated 4-week data on this patient and has given approval for the study to continue in the dilated cardiomyopathy cohort. Heartseed will continue to advance the clinical evaluation of HS-005. The cell utilized by Heartseed in cardiac remuscularization therapy is allogeneic iPS cell-derived, highly purified ventricular cardiomyocyte product formulated in spheroids. The non-clinical studies confirmed that forming micro-tissue-like spheroids enhances the cell retention rate and viability compared to single cells in their administration. When administering cardiomyocyte spheroids into the myocardial layer of the heart, HS-001 uses a proprietary delivery needle (SEEDPLANTER) and guide adapter developed in-house for epicardial delivery. In contrast, HS-005 utilizes a catheter system for endocardial delivery. The administered cardiomyocytes are expected to be engrafted into the patient's myocardium, promoting “remuscularization” and improving cardiac contractility. Additionally, they are anticipated to secrete various angiogenic factors, promoting neovascularization (formation of new blood vessels) around the administration sites. The EMERALD study is the Phase I/II clinical trial to proceed the development of HS-005 program which utilizes a catheter system for endocardial delivery to administer cardiomyocyte spheroids. In the EMERALD study, it aims at treating severe heart failure with reduced ejection fraction (HFrEF) with underlying ischemic heart disease as well as dilated cardiomyopathy, planning to enroll 7 patients in each cohort, for a total of 14 patients, to evaluate the safety and efficacy of the therapy. A phase I/II study of Endocardial delivery for Myocardial Regeneration using Allogeneic iPS cell-derived Cardiomyocyte Spheroids for Heart Failure with Systolic Dysfunction (EMERALD study) jRCT registration number: jRCT2033250454. The development of HS-005 utilized data obtained through the following support provided by Japan Agency for Medical Research and Development (AMED): Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy (Support for Accelerating the Development of Regenerative Medicine Seeds) "Evaluation of Quality and Safety and Regulatory Affairs for Transitioning to Clinical Trials Toward the Industrialization of iPS cell-Derived Regenerative Cardiomyocyte Transplantation Therapy" (Representative: Keiichi Fukuda) (Fiscal year 2018-Fiscal year 2020).Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to JP¥1,616, the stock trades at a trailing P/E ratio of 62.4x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total loss to shareholders of 45% over the past year.공시 • Jun 03Heartseed Inc. to Report Q2, 2026 Results on Aug 14, 2026Heartseed Inc. announced that they will report Q2, 2026 results on Aug 14, 2026Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to JP¥1,531, the stock trades at a trailing P/E ratio of 59.1x. Average trailing P/E is 36x in the Biotechs industry in Asia. Total loss to shareholders of 41% over the past year.공시 • May 09Heartseed Inc. to Report Q1, 2026 Results on May 15, 2026Heartseed Inc. announced that they will report Q1, 2026 results on May 15, 2026공시 • Feb 14Heartseed Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026Heartseed Inc. provided non-consolidated earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects net sales of JPY 451 million, Operating loss of JPY 2,207 million, Loss of JPY 2,158 million and Basic loss per share of JPY 95.58.공시 • Feb 13Heartseed Inc., Annual General Meeting, Mar 27, 2026Heartseed Inc., Annual General Meeting, Mar 27, 2026.공시 • Dec 27Heartseed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Heartseed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,806, the stock trades at a trailing P/E ratio of 69.5x. Average trailing P/E is 38x in the Biotechs industry in Asia. Total loss to shareholders of 29% over the past year.New Risk • Dec 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 37% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 37% per year for the foreseeable future.Valuation Update With 7 Day Price Move • Oct 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to JP¥1,727, the stock trades at a trailing P/E ratio of 75.8x. Average trailing P/E is 63x in the Biotechs industry in Japan. Total returns to shareholders of 17% over the past year.Buy Or Sell Opportunity • Oct 03Now 27% overvaluedOver the last 90 days, the stock has fallen 45% to JP¥1,526. The fair value is estimated to be JP¥1,198, however this is not to be taken as a sell recommendation but rather should be used as a guide only.공시 • Jul 31Heartseed Inc. to Report Q3, 2025 Results on Sep 11, 2025Heartseed Inc. announced that they will report Q3, 2025 results on Sep 11, 2025분석 기사 • May 26Here's Why We're Not At All Concerned With Heartseed's (TSE:219A) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • Apr 23Heartseed Inc. to Report Q2, 2025 Results on Jun 12, 2025Heartseed Inc. announced that they will report Q2, 2025 results on Jun 12, 2025공시 • Feb 03Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial Using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart FailureHeartseed Inc. announced the completion of patient enrollment for the 5th patient in high-dose arm, marking the 10th and final patient enrolled in its Phase I/II clinical trial (LAPiS Study) for HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid product for advanced heart failure due to ischaemic heart disease. As stated in the press release dated October 1, 2024, the Safety Monitoring Committee reviewed the safety data of the first patient in the high-dose cohort (150 million cardiomyocytes) of the LAPiS Study and recommended the continuation of enrollment for the high-dose group. Following this, patient dosing progressed smoothly, and the enrollment of all patients in the LAPiS Study has now been completed. About HS-001 and LAPiS Study: HS-001, is an allogeneic iPSC-derived, highly purified ventricular cardiomyocyte product formulated in spheroids. The micro-tissue-like spheroid preparation increases retention rate and viability of the cell graft. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for safe and efficient administration during open heart surgery. There are two expected mechanisms of action. Firstly, that the transplanted cardiomyocytes electrically couple with the patient's myocardium, improving cardiac output by remuscularization. Second, that secretion of angiogenic factors from the graft causes new blood vessel development around the transplant site (neovascularization). The LAPiS Study is a 52-week, phase 1/2, open-label, dose-escalation trial designed to evaluate the safety and efficacy of HS-001 in patients with advanced heart failure caused by ischaemic heart disease. Conducted at multiple sites in Japan, the study has successfully completed enrollment of 10 patients, divided into two cohorts: 5 in the low-dose group (50 million cardiomyocytes) and 5 in the high-dose group (150 million cardiomyocytes). HS-001 was transplanted into the diseased heart during scheduled open-heart surgeries (coronary artery bypass grafting). The primary endpoint of the study is safety at 26 weeks post-transplantation. Secondary efficacy endpoints, assessed at 26 and 52 weeks, include Left Ventricular Ejection Fraction and myocardial wall motion.분석 기사 • Jan 30Here's Why We're Not At All Concerned With Heartseed's (TSE:219A) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...공시 • Jan 28Heartseed Inc. to Report Q1, 2025 Results on Mar 13, 2025Heartseed Inc. announced that they will report Q1, 2025 results on Mar 13, 2025공시 • Dec 13Heartseed Inc., Annual General Meeting, Jan 24, 2025Heartseed Inc., Annual General Meeting, Jan 24, 2025.공시 • Oct 23Heartseed Inc. to Report Fiscal Year 2024 Results on Dec 12, 2024Heartseed Inc. announced that they will report fiscal year 2024 results on Dec 12, 2024공시 • Oct 18Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. revised earnings guidance for the fiscal year ending October 31, 2024. For the year, the company expects net sales of JPY 874 million compared to Previous forecast of JPY 153 million, Operating loss of JPY 1,059 million compared to Previous forecast of JPY 1,965 million, net income of JPY 891 million compared to Previous forecast of JPY 1,798 million, and Net loss Per Shares of JPY 54.32 compared to Previous forecast of JPY 109.09.공시 • Sep 13Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. provided earnings guidance for the fiscal year ending October 31, 2024. For the fiscal year, the company expected net sales of JPY 153 million, Operating loss of JPY 1,965 million, Net loss of JPY 1,798 million and Net loss per share of JPY 109.09.공시 • Aug 10Heartseed Inc. to Report Q3, 2024 Results on Sep 12, 2024Heartseed Inc. announced that they will report Q3, 2024 results on Sep 12, 2024공시 • Aug 01Heartseed Inc. has completed an IPO in the amount of ¥2.089972 billion.Heartseed Inc. has completed an IPO in the amount of ¥2.089972 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,413,700 Price\Range: ¥1160 Discount Per Security: ¥92.8 Security Name: Common Stock Security Type: Common Stock Securities Offered: 388,000 Price\Range: ¥1160 Discount Per Security: ¥92.8 Transaction Features: Sponsor Backed OfferingBoard Change • Jul 30Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Outside Director Toshiharu Furukawa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측TSE:219A - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028190-2,696-2,579N/A112/31/20275-2,875-3,045N/A112/31/2026451-2,160-2,977N/A110/31/20253,027592N/AN/AN/A7/31/20252,640519N/AN/AN/A4/30/20252,640615611626N/A10/31/2024874-813-1,357-1,343N/A10/31/2023345-1,473-1,126-798N/A애널리스트 향후 성장 전망수입 대 저축률: 219A 의 연간 예상 수익 증가율(0.7%)이 saving rate(0.8%) 미만입니다.수익 vs 시장: 219A 의 연간 수익(0.7%)이 JP 시장(10%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 219A 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 219A 의 수익(연간 41%)이 JP 시장(연간 6.5%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 219A 의 수익(연간 41%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 219A는 3년 뒤에도 수익성이 없을 것으로 전망됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/02 07:44종가2026/07/02 00:00수익2025/10/31연간 수익2025/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Heartseed Inc.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Motoya KohtaniMizuho Securities Co., Ltd.
공시 • Feb 14Heartseed Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026Heartseed Inc. provided non-consolidated earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects net sales of JPY 451 million, Operating loss of JPY 2,207 million, Loss of JPY 2,158 million and Basic loss per share of JPY 95.58.
공시 • Oct 18Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. revised earnings guidance for the fiscal year ending October 31, 2024. For the year, the company expects net sales of JPY 874 million compared to Previous forecast of JPY 153 million, Operating loss of JPY 1,059 million compared to Previous forecast of JPY 1,965 million, net income of JPY 891 million compared to Previous forecast of JPY 1,798 million, and Net loss Per Shares of JPY 54.32 compared to Previous forecast of JPY 109.09.
공시 • Sep 13Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. provided earnings guidance for the fiscal year ending October 31, 2024. For the fiscal year, the company expected net sales of JPY 153 million, Operating loss of JPY 1,965 million, Net loss of JPY 1,798 million and Net loss per share of JPY 109.09.
New Risk • Jun 29New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2025 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change).
공시 • Jun 12Heartseed Announces First Patient Dosed In Phase I/II Clinical Trial Of HS-005 For Cardiac Remuscularization TherapyHeartseed Inc. announced that the first patient with heart failure caused by dilated cardiomyopathy has been dosed in the domestic clinical trial (EMERALD study) of HS-005 (allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter), which is being developed by the Company. The Independent Safety Monitoring Committee approved the continuation of the trial for dilated cardiomyopathy cohort based on the evaluation of four-week post-administration data from this case. This trial is a company-sponsored clinical trial aimed at expanding the application of the therapy not only to severe heart failure caused by ischemic heart disease, but also by dilated cardiomyopathy. A total of 14 patients, consisting of seven patients in each disease cohort, will be enrolled to evaluate the safety and efficacy of the therapy. There is no revision to the latest earnings forecast for the fiscal year ending December 31, 2026. Heartseed Inc. announced the successful dosing of the first patient in its domestic Phase I/II clinical trial (EMERALD study) of HS-005, allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter, targeting severe heart failure caused by ischemic heart disease or dilated cardiomyopathy. This study marks the world's first clinical trial to administer iPS cell-derived cardiomyocyte spheroids using a catheter. HS-005 is a therapeutic program currently under development, in which allogeneic iPS cell-derived cardiomyocyte spheroids (micro-tissues of cardiomyocytes) produced based on Heartseed's proprietary technology are administered into the patient's myocardium using a dedicated delivery catheter system. While Heartseed's lead pipeline, HS-001, requires open-heart surgery, HS-005 utilizes a catheter for delivery from the inside of the heart (endocardial delivery), aiming to realize a next-generation, minimally invasive cardiac regenerative medicine. Heartseed has been advancing the EMERALD study in Japan aiming at the development of HS-005, and the administration to the first patient suffering from heart failure due to dilated cardiomyopathy was successfully completed in late March 2026 at Shinshu University Hospital. The patient's postoperative course has been generally uneventful, and the patient has already been discharged from the hospital. The independent Safety Monitoring Committee has evaluated 4-week data on this patient and has given approval for the study to continue in the dilated cardiomyopathy cohort. Heartseed will continue to advance the clinical evaluation of HS-005. The cell utilized by Heartseed in cardiac remuscularization therapy is allogeneic iPS cell-derived, highly purified ventricular cardiomyocyte product formulated in spheroids. The non-clinical studies confirmed that forming micro-tissue-like spheroids enhances the cell retention rate and viability compared to single cells in their administration. When administering cardiomyocyte spheroids into the myocardial layer of the heart, HS-001 uses a proprietary delivery needle (SEEDPLANTER) and guide adapter developed in-house for epicardial delivery. In contrast, HS-005 utilizes a catheter system for endocardial delivery. The administered cardiomyocytes are expected to be engrafted into the patient's myocardium, promoting “remuscularization” and improving cardiac contractility. Additionally, they are anticipated to secrete various angiogenic factors, promoting neovascularization (formation of new blood vessels) around the administration sites. The EMERALD study is the Phase I/II clinical trial to proceed the development of HS-005 program which utilizes a catheter system for endocardial delivery to administer cardiomyocyte spheroids. In the EMERALD study, it aims at treating severe heart failure with reduced ejection fraction (HFrEF) with underlying ischemic heart disease as well as dilated cardiomyopathy, planning to enroll 7 patients in each cohort, for a total of 14 patients, to evaluate the safety and efficacy of the therapy. A phase I/II study of Endocardial delivery for Myocardial Regeneration using Allogeneic iPS cell-derived Cardiomyocyte Spheroids for Heart Failure with Systolic Dysfunction (EMERALD study) jRCT registration number: jRCT2033250454. The development of HS-005 utilized data obtained through the following support provided by Japan Agency for Medical Research and Development (AMED): Basic Technology Development Project for Industrialization of Regenerative Medicine and Gene Therapy (Support for Accelerating the Development of Regenerative Medicine Seeds) "Evaluation of Quality and Safety and Regulatory Affairs for Transitioning to Clinical Trials Toward the Industrialization of iPS cell-Derived Regenerative Cardiomyocyte Transplantation Therapy" (Representative: Keiichi Fukuda) (Fiscal year 2018-Fiscal year 2020).
Valuation Update With 7 Day Price Move • Jun 08Investor sentiment improves as stock rises 15%After last week's 15% share price gain to JP¥1,616, the stock trades at a trailing P/E ratio of 62.4x. Average trailing P/E is 30x in the Biotechs industry in Asia. Total loss to shareholders of 45% over the past year.
공시 • Jun 03Heartseed Inc. to Report Q2, 2026 Results on Aug 14, 2026Heartseed Inc. announced that they will report Q2, 2026 results on Aug 14, 2026
Valuation Update With 7 Day Price Move • May 20Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to JP¥1,531, the stock trades at a trailing P/E ratio of 59.1x. Average trailing P/E is 36x in the Biotechs industry in Asia. Total loss to shareholders of 41% over the past year.
공시 • May 09Heartseed Inc. to Report Q1, 2026 Results on May 15, 2026Heartseed Inc. announced that they will report Q1, 2026 results on May 15, 2026
공시 • Feb 14Heartseed Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2026Heartseed Inc. provided non-consolidated earnings guidance for the fiscal year ending December 31, 2026. For the year, the company expects net sales of JPY 451 million, Operating loss of JPY 2,207 million, Loss of JPY 2,158 million and Basic loss per share of JPY 95.58.
공시 • Feb 13Heartseed Inc., Annual General Meeting, Mar 27, 2026Heartseed Inc., Annual General Meeting, Mar 27, 2026.
공시 • Dec 27Heartseed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026Heartseed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,806, the stock trades at a trailing P/E ratio of 69.5x. Average trailing P/E is 38x in the Biotechs industry in Asia. Total loss to shareholders of 29% over the past year.
New Risk • Dec 04New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 37% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 37% per year for the foreseeable future.
Valuation Update With 7 Day Price Move • Oct 09Investor sentiment improves as stock rises 24%After last week's 24% share price gain to JP¥1,727, the stock trades at a trailing P/E ratio of 75.8x. Average trailing P/E is 63x in the Biotechs industry in Japan. Total returns to shareholders of 17% over the past year.
Buy Or Sell Opportunity • Oct 03Now 27% overvaluedOver the last 90 days, the stock has fallen 45% to JP¥1,526. The fair value is estimated to be JP¥1,198, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
공시 • Jul 31Heartseed Inc. to Report Q3, 2025 Results on Sep 11, 2025Heartseed Inc. announced that they will report Q3, 2025 results on Sep 11, 2025
분석 기사 • May 26Here's Why We're Not At All Concerned With Heartseed's (TSE:219A) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • Apr 23Heartseed Inc. to Report Q2, 2025 Results on Jun 12, 2025Heartseed Inc. announced that they will report Q2, 2025 results on Jun 12, 2025
공시 • Feb 03Heartseed Announces Enrollment Completion in Phase 1/2 Clinical Trial Using HS-001, an Investigational Stem Cell-Derived Therapy for Advanced Heart FailureHeartseed Inc. announced the completion of patient enrollment for the 5th patient in high-dose arm, marking the 10th and final patient enrolled in its Phase I/II clinical trial (LAPiS Study) for HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid product for advanced heart failure due to ischaemic heart disease. As stated in the press release dated October 1, 2024, the Safety Monitoring Committee reviewed the safety data of the first patient in the high-dose cohort (150 million cardiomyocytes) of the LAPiS Study and recommended the continuation of enrollment for the high-dose group. Following this, patient dosing progressed smoothly, and the enrollment of all patients in the LAPiS Study has now been completed. About HS-001 and LAPiS Study: HS-001, is an allogeneic iPSC-derived, highly purified ventricular cardiomyocyte product formulated in spheroids. The micro-tissue-like spheroid preparation increases retention rate and viability of the cell graft. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for safe and efficient administration during open heart surgery. There are two expected mechanisms of action. Firstly, that the transplanted cardiomyocytes electrically couple with the patient's myocardium, improving cardiac output by remuscularization. Second, that secretion of angiogenic factors from the graft causes new blood vessel development around the transplant site (neovascularization). The LAPiS Study is a 52-week, phase 1/2, open-label, dose-escalation trial designed to evaluate the safety and efficacy of HS-001 in patients with advanced heart failure caused by ischaemic heart disease. Conducted at multiple sites in Japan, the study has successfully completed enrollment of 10 patients, divided into two cohorts: 5 in the low-dose group (50 million cardiomyocytes) and 5 in the high-dose group (150 million cardiomyocytes). HS-001 was transplanted into the diseased heart during scheduled open-heart surgeries (coronary artery bypass grafting). The primary endpoint of the study is safety at 26 weeks post-transplantation. Secondary efficacy endpoints, assessed at 26 and 52 weeks, include Left Ventricular Ejection Fraction and myocardial wall motion.
분석 기사 • Jan 30Here's Why We're Not At All Concerned With Heartseed's (TSE:219A) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, although...
공시 • Jan 28Heartseed Inc. to Report Q1, 2025 Results on Mar 13, 2025Heartseed Inc. announced that they will report Q1, 2025 results on Mar 13, 2025
공시 • Dec 13Heartseed Inc., Annual General Meeting, Jan 24, 2025Heartseed Inc., Annual General Meeting, Jan 24, 2025.
공시 • Oct 23Heartseed Inc. to Report Fiscal Year 2024 Results on Dec 12, 2024Heartseed Inc. announced that they will report fiscal year 2024 results on Dec 12, 2024
공시 • Oct 18Heartseed Inc. Revises Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. revised earnings guidance for the fiscal year ending October 31, 2024. For the year, the company expects net sales of JPY 874 million compared to Previous forecast of JPY 153 million, Operating loss of JPY 1,059 million compared to Previous forecast of JPY 1,965 million, net income of JPY 891 million compared to Previous forecast of JPY 1,798 million, and Net loss Per Shares of JPY 54.32 compared to Previous forecast of JPY 109.09.
공시 • Sep 13Heartseed Inc. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2024Heartseed Inc. provided earnings guidance for the fiscal year ending October 31, 2024. For the fiscal year, the company expected net sales of JPY 153 million, Operating loss of JPY 1,965 million, Net loss of JPY 1,798 million and Net loss per share of JPY 109.09.
공시 • Aug 10Heartseed Inc. to Report Q3, 2024 Results on Sep 12, 2024Heartseed Inc. announced that they will report Q3, 2024 results on Sep 12, 2024
공시 • Aug 01Heartseed Inc. has completed an IPO in the amount of ¥2.089972 billion.Heartseed Inc. has completed an IPO in the amount of ¥2.089972 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,413,700 Price\Range: ¥1160 Discount Per Security: ¥92.8 Security Name: Common Stock Security Type: Common Stock Securities Offered: 388,000 Price\Range: ¥1160 Discount Per Security: ¥92.8 Transaction Features: Sponsor Backed Offering
Board Change • Jul 30Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Outside Director Toshiharu Furukawa was the last independent director to join the board, commencing their role in 2017. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.